AR076407A1 - Un proceso para la preparacion de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-metilcarbamilmetil)piperidin-4-il]oxi}quinazolina e intermediarios utilizados en el mismo. - Google Patents

Un proceso para la preparacion de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-metilcarbamilmetil)piperidin-4-il]oxi}quinazolina e intermediarios utilizados en el mismo.

Info

Publication number
AR076407A1
AR076407A1 ARP100101374A ARP100101374A AR076407A1 AR 076407 A1 AR076407 A1 AR 076407A1 AR P100101374 A ARP100101374 A AR P100101374A AR P100101374 A ARP100101374 A AR P100101374A AR 076407 A1 AR076407 A1 AR 076407A1
Authority
AR
Argentina
Prior art keywords
chloro
formula
fluoroanilino
quinazoline
piperidin
Prior art date
Application number
ARP100101374A
Other languages
English (en)
Spanish (es)
Inventor
Kay Alison Boardman
Oliver Robert Cunningham
David Dermot Patrick Laffan
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR076407A1 publication Critical patent/AR076407A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/12Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
ARP100101374A 2009-04-23 2010-04-23 Un proceso para la preparacion de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-metilcarbamilmetil)piperidin-4-il]oxi}quinazolina e intermediarios utilizados en el mismo. AR076407A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17199409P 2009-04-23 2009-04-23

Publications (1)

Publication Number Publication Date
AR076407A1 true AR076407A1 (es) 2011-06-08

Family

ID=42224659

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100101374A AR076407A1 (es) 2009-04-23 2010-04-23 Un proceso para la preparacion de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-metilcarbamilmetil)piperidin-4-il]oxi}quinazolina e intermediarios utilizados en el mismo.

Country Status (14)

Country Link
US (1) US8450482B2 (https=)
EP (1) EP2421827A2 (https=)
JP (1) JP2012524769A (https=)
KR (1) KR20120007059A (https=)
CN (1) CN102459174A (https=)
AR (1) AR076407A1 (https=)
AU (1) AU2010240717A1 (https=)
BR (1) BRPI1013854A2 (https=)
CA (1) CA2758610A1 (https=)
IL (1) IL215388A0 (https=)
MX (1) MX2011011177A (https=)
SG (1) SG174893A1 (https=)
TW (1) TW201041871A (https=)
WO (1) WO2010122340A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101272613B1 (ko) * 2011-10-05 2013-06-10 한미사이언스 주식회사 1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온 염산염의 제조 방법 및 이에 사용되는 중간체
CN108503596A (zh) * 2018-03-14 2018-09-07 盐城师范学院 一种新的厄洛替尼及其中间体的制备方法
CN108440420A (zh) * 2018-03-22 2018-08-24 盐城师范学院 酪氨酸激酶抑制剂拉帕替尼及其关键中间体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI324597B (en) 2002-03-28 2010-05-11 Astrazeneca Ab Quinazoline derivatives
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
GB0320793D0 (en) * 2003-09-05 2003-10-08 Astrazeneca Ab Chemical process
WO2005028469A1 (en) * 2003-09-19 2005-03-31 Astrazeneca Ab Quinazoline derivatives
WO2005115145A2 (en) * 2004-05-20 2005-12-08 Wyeth Quinone substituted quinazoline and quinoline kinase inhibitors
EP2303276B1 (en) * 2008-05-13 2013-11-13 AstraZeneca AB Fumarate salt of 4-(3-chloro-2-fluoroanilino)-7-methoxy-6-{[1-(n-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline
WO2009138779A1 (en) 2008-05-13 2009-11-19 Astrazeneca Ab Combination comprising 4- (3-chloro-2-fluoroanilino) -7-meth0xy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxyjquinazoline

Also Published As

Publication number Publication date
TW201041871A (en) 2010-12-01
SG174893A1 (en) 2011-11-28
US20120108814A1 (en) 2012-05-03
KR20120007059A (ko) 2012-01-19
WO2010122340A2 (en) 2010-10-28
MX2011011177A (es) 2011-11-18
JP2012524769A (ja) 2012-10-18
WO2010122340A8 (en) 2011-12-15
CA2758610A1 (en) 2010-10-28
EP2421827A2 (en) 2012-02-29
IL215388A0 (en) 2011-12-29
CN102459174A (zh) 2012-05-16
AU2010240717A1 (en) 2011-10-27
WO2010122340A3 (en) 2011-09-09
BRPI1013854A2 (pt) 2017-05-16
US8450482B2 (en) 2013-05-28

Similar Documents

Publication Publication Date Title
PE20220430A1 (es) PROCESO PARA LA SINTESIS DE 4-({2-[(AMINOSULFONIL)AMINO]ETIL}AMINO)-N-(3-BROMO-4-FLUOROFENILl)-N'-HIDROXI-1,2,5-OXADIAZOL-3-CARBOXIMIDAMIDA UN INHIBIDOR DE INDOLAMINA 2,3-DIOXIGENASA
SV2009002865A (es) Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias
ECSP099078A (es) Derivados de amino-piperidina como inhibidores de la proteina de transferencia de colesteril-ester (cetp)
CU24053B1 (es) Sales de disacarina, ácido difumárico, ácido di-1-hidroxi-2-naftoico y ácido monobenzoico del 2-(4-((2-amino-4-metil-6-(pentilamino)pirimidin-5-il)metil)fenil)acetato de 4-(dimetilamino)butilo
CO6251282A2 (es) Oxazolidinonas sustituidas y su uso
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
UY30136A1 (es) Sal especifica, forma anhidra y cristalina de un derivado de dihidropteridiona
CR11793A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
GT200600086A (es) Forma cristalina de gamma-d del clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
CY1117424T1 (el) Βενζοδιαζεπινικος αναστολεας bromodomain
BRPI0905147A8 (pt) processo para síntese de ivabradina e seus sais de adição com um ácido farmaceuticamente aceitável
AR085308A1 (es) Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2-(1-hidroxi-1-metil-etil)pirimidin-5-il]-7-(tetrahidrofuran-2-il)-1h-benzimidazol-2-il]urea
ECSP11010878A (es) Formas cristalinas de un derivado de 2-tiazolil-4-quinolinil-oxi, un potente inhibidor de hcv.
MX343611B (es) Composicion de control de fitoenfermedades y su uso.
UY32062A (es) Inhibidores de beta-secretasa
UY32096A (es) Derivados de 2-carboxamida - cicloamino - urea especìficos, sus sales farmacèuticamente aceptables, composiciones contenièndolos, pro-farmacos de los mismos, procesos para su produciòn y aplicaciones
EA201000884A1 (ru) Производные 1,2-дизамещенного 4-бензиламинопирролидина в качестве ингибиторов белка-переносчика холестерилового эфира, используемые для лечения заболеваний, таких как гиперлипидемия или артериосклероз
AR063923A1 (es) Sales del acido zoledronico, procesos de preparacion y composiciones
PE20140966A1 (es) Quinazolincarboxamida azetidinas
UY32877A (es) Inhibidores heteroarílicos de cinasa.
MX2010005005A (es) Limpiador dental.
UA109290C2 (uk) Спільні кристали і солі інгібіторів ccr3
CR11859A (es) Composición y proceso-356
AR076407A1 (es) Un proceso para la preparacion de 4-(3-cloro-2-fluoroanilino)-7-metoxi-6-{[1-(n-metilcarbamilmetil)piperidin-4-il]oxi}quinazolina e intermediarios utilizados en el mismo.
MX369690B (es) Diacilhidrazina cristalina y sus usos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal